metropolis
本站元老
- 注册
- 2010-12-10
- 消息
- 8,259
- 荣誉分数
- 1,503
- 声望点数
- 323
1992年中国60%的人感染过乙肝病毒，1.2亿病毒携带者。
1994年默克公司总裁罗依.瓦杰洛斯（Roy Vogelos)博士以赔本的700万美元向中国转让乙肝疫苗的技术，还负责全方位培训，建厂，默克所花费的费用远超700万。今年93岁的Dr. Vogelos说这是默克公司在20世纪做出的最好的商业决策之一，虽然没有利润，但是拯救的生命数超过默克制药公司所做的任何事，因为这个决定，中国有望在50年后根除乙肝疾病。
“It is the right thing to do! This is one of Merck’s best business decisions in the 20th century. Even though there is no profit, the number of lives saved exceeds anything that Merck Pharmaceuticals has done and because of this decision, China will be able to eradicate hepatitis B disease in 50 years’ time.”
“At first we wanted to sell the hepatitis B vaccine to China. However, after realizing that even if we reduced the pricing to the lowest possible, China still could not afford it. In the United States, the vaccine has to be injected three times within six months at the cost of US$100, which is most affordable to American families but to the average Chinese family, this is equivalent to their income for half a year.
In view of this, we started to discuss a technology transfer. We repeatedly reduced the price, yet China still could not afford it. I was very anxious and time was pressing. I wanted to protect all the children in China against this deadly disease. All newborns have to be vaccinated within 24 hours of birth. Finally, I proposed US$7 million to transfer the technology to China.”
“We must always remember the motto that in the medical field, it is people-oriented and not for profit; profit will come later. We must always remember this point. We want to bring the best invention to everyone who needs it, not just for those who can afford it, because life is priceless.”
www.163.com
1994年默克公司总裁罗依.瓦杰洛斯（Roy Vogelos)博士以赔本的700万美元向中国转让乙肝疫苗的技术，还负责全方位培训，建厂，默克所花费的费用远超700万。今年93岁的Dr. Vogelos说这是默克公司在20世纪做出的最好的商业决策之一，虽然没有利润，但是拯救的生命数超过默克制药公司所做的任何事，因为这个决定，中国有望在50年后根除乙肝疾病。
“It is the right thing to do! This is one of Merck’s best business decisions in the 20th century. Even though there is no profit, the number of lives saved exceeds anything that Merck Pharmaceuticals has done and because of this decision, China will be able to eradicate hepatitis B disease in 50 years’ time.”
“At first we wanted to sell the hepatitis B vaccine to China. However, after realizing that even if we reduced the pricing to the lowest possible, China still could not afford it. In the United States, the vaccine has to be injected three times within six months at the cost of US$100, which is most affordable to American families but to the average Chinese family, this is equivalent to their income for half a year.
In view of this, we started to discuss a technology transfer. We repeatedly reduced the price, yet China still could not afford it. I was very anxious and time was pressing. I wanted to protect all the children in China against this deadly disease. All newborns have to be vaccinated within 24 hours of birth. Finally, I proposed US$7 million to transfer the technology to China.”
“We must always remember the motto that in the medical field, it is people-oriented and not for profit; profit will come later. We must always remember this point. We want to bring the best invention to everyone who needs it, not just for those who can afford it, because life is priceless.”
李永乐老师：乙肝病毒如何疯狂感染全球20亿人？第一支乙肝疫苗是如何诞生的？
How Merck's Decision Saved Millions of Lives in China
Merck & Co. Inc. (MRK), the largest U.S. pharmaceutical company, transferred its genetically engineered hepatitis B vaccine technology
www.nspirement.com
1994年，美国药商将乙肝疫苗技术转让中国，是大爱无疆还是另有…
1994年，美国药商将乙肝疫苗技术转让中国，是大爱无疆还是另有…,乙肝疫苗,疫苗,乙肝,中国,默沙东公司,瓦杰洛
www.163.com
